MEDX Xelerator

MEDX Xelerator is a medical device incubator based in Or Yehuda, Israel, operating under the Israel Innovation Authority’s incubator program with strategic backing from Boston Scientific, Intellectsy, and Sheba Medical Center. That sponsor list is not decorative. It defines the kind of company MEDX is built to launch: minimally invasive cardiovascular, structural heart, robotic, urology, and image-guided device companies that benefit from clinical access at Sheba and a credible commercial reference point at one of the world’s largest medical device strategics.

The incubator’s thesis is concentrated on early-stage device concepts where a clear unmet clinical need intersects with engineering tractable enough to reach first-in-human within a defined window. AI is increasingly woven into that mandate, particularly around procedural guidance, automated imaging analysis, navigation, and intra-operative decision support that augments hardware platforms. Companies emerging from MEDX typically combine a physical instrument or implant with software that improves placement, sizing, or workflow. Pure software plays without a device anchor are not the typical fit.

Check sizes for the first round generally fall in the $250k to $1M range, supplemented by significant non-dilutive support from the Israel Innovation Authority, which can extend the runway substantially. Companies admitted to the incubator gain access to laboratories, prototyping facilities, regulatory and quality consultants, and early clinical collaboration with Sheba. The geographic focus is Israel, with the explicit expectation that companies will pursue US and European markets as commercial targets. Stage is pre-seed to seed, and follow-on capital typically arrives from Peregrine, aMoon, Boston Scientific itself in select cases, and other Israeli healthtech specialists.

The team blends investment professionals with operators carrying device industry resumes, including former engineering and clinical leaders from Boston Scientific and other strategics. They function as hands-on co-builders rather than passive board members, which is appropriate given the typical maturity of the companies entering the program.

Founders should approach MEDX with a defined clinical problem, a defensible IP position or clear path to one, and a willingness to operate inside an incubator structure for the first 24 to 36 months. The intake process runs through a formal application and review, often initiated through introductions from physicians at Sheba, alumni founders, or device industry contacts who know the program. The right moment to apply is when a concept has progressed past back-of-the-envelope and the team can articulate a credible regulatory pathway, a target indication, and a reasoned view on reimbursement, but before significant capital has been raised elsewhere. Founders entirely committed to a software-only product, those unwilling to build clinical relationships in Israel, or those who need a $5M Series A immediately should look elsewhere. For device-software hybrids targeting cardiovascular, urology, or robotic procedures, MEDX is among the most strategically aligned entry points in the global ecosystem.